Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
21 nov. 2022 10h31 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application...
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
10 nov. 2022 16h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview...
Vaccitech to Present at Upcoming November Investors Conferences
09 nov. 2022 08h00 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies...
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B
07 nov. 2022 08h00 HE
|
Vaccitech plc
VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial. VTP-300 as a monotherapy and in...
Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300
02 nov. 2022 08h00 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
31 oct. 2022 08h00 HE
|
Vaccitech plc
OXFORD, United Kingdom, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm
27 oct. 2022 07h00 HE
|
Vaccitech plc
Vaccitech collaborators at NIH’s Vaccine Research Center demonstrate that IV administration of SNAPvax in animal models activates two key pathways leading to improved T cell mediated tumor killing in...
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
03 oct. 2022 16h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Promotes Gemma Brown as Chief Financial Officer
20 sept. 2022 16h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at Upcoming September Investors Conferences
07 sept. 2022 16h01 HE
|
Vaccitech plc
OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...